HDAC isoforms show a variable expression profile in prostate cancer cells, thereby their response to HDACi is not uniform, but cell line-, target- and inhibitor-specific (Waltregny et al., 2004; Kortenhorst et al., 2013). The gene discussed is HDAC9; the disease is prostate carcinoma.